Astellas Pharma and Medivation have announced the submission of marketing authorization application (MAA) to the European Medicines Agency (EMA) for enzalutamide to treat metastatic castration-resistant prostate cancer in men who have ...
Tags: enzalutamide, metastatic castration-resistant prostate cancer
Carbon design Group has signed Irish Malig as Senior Design Researcher & Strategist. “Irish is a terrific addition to our team,” commented Linda Wagner, Carbon’s Director of Research & Strategy. “She demonstrates a ...
Tags: Irish Malig, Carbon Design Group, Memorial Sloan-Kettering Cancer Center
The US Food and Drug Administration (FDA) has approved Genentech's Perjeta (pertuzumab) for the treatment of HER2-positive metastatic breast cancer (mBC), in combination with Herceptin (trastuzumab) and docetaxel chemotherapy. The ...
Tags: FDA approval, breast cancer, clinical study, pharmaceutical product
The European Commission (EC) has awarded a conditional marketing authorization approval for Cell Therapeutics' Pixuvri (pixantrone) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive ...
Tags: marketing authorization, pharmaceutical product, Pixuvri
EpiCept has received fast track designation for AmiKet (amitriptyline 4%, ketamine 2% cream) from the US Food and Drug Administration (FDA). AmiKet is indicated for the treatment of neuropathic pain associated with ...
Tags: FDA, fast track designation, treatment of neuropathic pain
More than 80 percent of people with pancreatic cancer are diagnosed after the cancer has metastasized, and by then the prognosis for long-term survival is dismal. However, surgeons and scientists at the University of California-San Diego ...
Tags: fluorescent light
More than 80 percent of people with pancreatic cancer are diagnosed after the cancer has metastasized, and by then the prognosis for long-term survival is dismal. However, surgeons and scientists at the University of California-San Diego ...
Tags: Market View, fluorescent light